Sequential use of indium-111 labeled monoclonal antibodies 96.5 and ZME-018 does not increase detection sensitivity for metastatic melanoma

M. Frontiera, J. L. Murray, L. Lamki, J. Thomas, W. Satterlee, R. Schmelter, M. G. Rosenblum, M. B. Khazaeli, M. W. Unger, W. A. Robinson, P. A. Bunn

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Two indium-111 labeled anti-melanoma murine monoclonal antibodies (MAb), 96.5 and ZME-018, each recognizing separate antigens on melanoma cells, were administered intravenously to 17 patients with melanoma in a sequential fashion to determine whether: 1) additional tumor sites could be imaged with the combination compared to a single MAb; 2) the first MAb influenced the biodistribution and tumor localization of the second; and 3) significant toxicity occurred with the combination. Patients were randomized to receive either 96.5, followed by ZME-018, ZME-018 followed by 96.5, or each MAb followed by itself (controls). Infusion of the second MAb occurred 10 days after the first infusion. Gamma camera images were obtained 72 hours after each antibody infusion. There were 139 known metastatic sites of which 72 lesions were localized by either MAb for an overall sensitivity of 52%. The detection rate was higher when lesions only greater than 1.5 cm were considered. Imaging results were independent of MAb administration sequence. When ZME-018 was given as the first infusion, 53% of known lesions were detected, compared to 34% when ZME-018 was given as a second infusion (p = NS). However, mean sensitivities using 96.5 as the first or second infusion were 48% and 66% respectively (p = NS). There was not a significant number of sites detected by MAb 2 that were missed by MAb 1. Human anti-murine antibody (HAMA) response occurred in seven of eight patients studied; two patients who experienced toxicity had levels of HAMA greater than 2000 ng/ml. We conclude that the use of these two murine anti-melanoma monoclonal antibodies given in sequential fashion did not significantly change the imaging sensitivity from that seen with each individual antibody. Moreover, with the exception of one patient, mean plasma half-life of the MAb did not change significantly, suggesting that overall clearance mechanisms were not saturated by the consecutive doses of monoclonal antibody or significantly altered by the presence of HAMA.

Original languageEnglish
Pages (from-to)357-366
Number of pages10
JournalClinical Nuclear Medicine
Volume14
Issue number5
Publication statusPublished - 1989

Fingerprint

Indium
Melanoma
Monoclonal Antibodies
Anti-Idiotypic Antibodies
Melanoma-Specific Antigens
Gamma Cameras
Antibodies
Antibody Formation
Half-Life
Neoplasms

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Radiological and Ultrasound Technology

Cite this

Sequential use of indium-111 labeled monoclonal antibodies 96.5 and ZME-018 does not increase detection sensitivity for metastatic melanoma. / Frontiera, M.; Murray, J. L.; Lamki, L.; Thomas, J.; Satterlee, W.; Schmelter, R.; Rosenblum, M. G.; Khazaeli, M. B.; Unger, M. W.; Robinson, W. A.; Bunn, P. A.

In: Clinical Nuclear Medicine, Vol. 14, No. 5, 1989, p. 357-366.

Research output: Contribution to journalArticle

Frontiera, M, Murray, JL, Lamki, L, Thomas, J, Satterlee, W, Schmelter, R, Rosenblum, MG, Khazaeli, MB, Unger, MW, Robinson, WA & Bunn, PA 1989, 'Sequential use of indium-111 labeled monoclonal antibodies 96.5 and ZME-018 does not increase detection sensitivity for metastatic melanoma', Clinical Nuclear Medicine, vol. 14, no. 5, pp. 357-366.
Frontiera, M. ; Murray, J. L. ; Lamki, L. ; Thomas, J. ; Satterlee, W. ; Schmelter, R. ; Rosenblum, M. G. ; Khazaeli, M. B. ; Unger, M. W. ; Robinson, W. A. ; Bunn, P. A. / Sequential use of indium-111 labeled monoclonal antibodies 96.5 and ZME-018 does not increase detection sensitivity for metastatic melanoma. In: Clinical Nuclear Medicine. 1989 ; Vol. 14, No. 5. pp. 357-366.
@article{c62b2da1578e4ff8b0d79294fd03f97c,
title = "Sequential use of indium-111 labeled monoclonal antibodies 96.5 and ZME-018 does not increase detection sensitivity for metastatic melanoma",
abstract = "Two indium-111 labeled anti-melanoma murine monoclonal antibodies (MAb), 96.5 and ZME-018, each recognizing separate antigens on melanoma cells, were administered intravenously to 17 patients with melanoma in a sequential fashion to determine whether: 1) additional tumor sites could be imaged with the combination compared to a single MAb; 2) the first MAb influenced the biodistribution and tumor localization of the second; and 3) significant toxicity occurred with the combination. Patients were randomized to receive either 96.5, followed by ZME-018, ZME-018 followed by 96.5, or each MAb followed by itself (controls). Infusion of the second MAb occurred 10 days after the first infusion. Gamma camera images were obtained 72 hours after each antibody infusion. There were 139 known metastatic sites of which 72 lesions were localized by either MAb for an overall sensitivity of 52{\%}. The detection rate was higher when lesions only greater than 1.5 cm were considered. Imaging results were independent of MAb administration sequence. When ZME-018 was given as the first infusion, 53{\%} of known lesions were detected, compared to 34{\%} when ZME-018 was given as a second infusion (p = NS). However, mean sensitivities using 96.5 as the first or second infusion were 48{\%} and 66{\%} respectively (p = NS). There was not a significant number of sites detected by MAb 2 that were missed by MAb 1. Human anti-murine antibody (HAMA) response occurred in seven of eight patients studied; two patients who experienced toxicity had levels of HAMA greater than 2000 ng/ml. We conclude that the use of these two murine anti-melanoma monoclonal antibodies given in sequential fashion did not significantly change the imaging sensitivity from that seen with each individual antibody. Moreover, with the exception of one patient, mean plasma half-life of the MAb did not change significantly, suggesting that overall clearance mechanisms were not saturated by the consecutive doses of monoclonal antibody or significantly altered by the presence of HAMA.",
author = "M. Frontiera and Murray, {J. L.} and L. Lamki and J. Thomas and W. Satterlee and R. Schmelter and Rosenblum, {M. G.} and Khazaeli, {M. B.} and Unger, {M. W.} and Robinson, {W. A.} and Bunn, {P. A.}",
year = "1989",
language = "English",
volume = "14",
pages = "357--366",
journal = "Clinical Nuclear Medicine",
issn = "0363-9762",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Sequential use of indium-111 labeled monoclonal antibodies 96.5 and ZME-018 does not increase detection sensitivity for metastatic melanoma

AU - Frontiera, M.

AU - Murray, J. L.

AU - Lamki, L.

AU - Thomas, J.

AU - Satterlee, W.

AU - Schmelter, R.

AU - Rosenblum, M. G.

AU - Khazaeli, M. B.

AU - Unger, M. W.

AU - Robinson, W. A.

AU - Bunn, P. A.

PY - 1989

Y1 - 1989

N2 - Two indium-111 labeled anti-melanoma murine monoclonal antibodies (MAb), 96.5 and ZME-018, each recognizing separate antigens on melanoma cells, were administered intravenously to 17 patients with melanoma in a sequential fashion to determine whether: 1) additional tumor sites could be imaged with the combination compared to a single MAb; 2) the first MAb influenced the biodistribution and tumor localization of the second; and 3) significant toxicity occurred with the combination. Patients were randomized to receive either 96.5, followed by ZME-018, ZME-018 followed by 96.5, or each MAb followed by itself (controls). Infusion of the second MAb occurred 10 days after the first infusion. Gamma camera images were obtained 72 hours after each antibody infusion. There were 139 known metastatic sites of which 72 lesions were localized by either MAb for an overall sensitivity of 52%. The detection rate was higher when lesions only greater than 1.5 cm were considered. Imaging results were independent of MAb administration sequence. When ZME-018 was given as the first infusion, 53% of known lesions were detected, compared to 34% when ZME-018 was given as a second infusion (p = NS). However, mean sensitivities using 96.5 as the first or second infusion were 48% and 66% respectively (p = NS). There was not a significant number of sites detected by MAb 2 that were missed by MAb 1. Human anti-murine antibody (HAMA) response occurred in seven of eight patients studied; two patients who experienced toxicity had levels of HAMA greater than 2000 ng/ml. We conclude that the use of these two murine anti-melanoma monoclonal antibodies given in sequential fashion did not significantly change the imaging sensitivity from that seen with each individual antibody. Moreover, with the exception of one patient, mean plasma half-life of the MAb did not change significantly, suggesting that overall clearance mechanisms were not saturated by the consecutive doses of monoclonal antibody or significantly altered by the presence of HAMA.

AB - Two indium-111 labeled anti-melanoma murine monoclonal antibodies (MAb), 96.5 and ZME-018, each recognizing separate antigens on melanoma cells, were administered intravenously to 17 patients with melanoma in a sequential fashion to determine whether: 1) additional tumor sites could be imaged with the combination compared to a single MAb; 2) the first MAb influenced the biodistribution and tumor localization of the second; and 3) significant toxicity occurred with the combination. Patients were randomized to receive either 96.5, followed by ZME-018, ZME-018 followed by 96.5, or each MAb followed by itself (controls). Infusion of the second MAb occurred 10 days after the first infusion. Gamma camera images were obtained 72 hours after each antibody infusion. There were 139 known metastatic sites of which 72 lesions were localized by either MAb for an overall sensitivity of 52%. The detection rate was higher when lesions only greater than 1.5 cm were considered. Imaging results were independent of MAb administration sequence. When ZME-018 was given as the first infusion, 53% of known lesions were detected, compared to 34% when ZME-018 was given as a second infusion (p = NS). However, mean sensitivities using 96.5 as the first or second infusion were 48% and 66% respectively (p = NS). There was not a significant number of sites detected by MAb 2 that were missed by MAb 1. Human anti-murine antibody (HAMA) response occurred in seven of eight patients studied; two patients who experienced toxicity had levels of HAMA greater than 2000 ng/ml. We conclude that the use of these two murine anti-melanoma monoclonal antibodies given in sequential fashion did not significantly change the imaging sensitivity from that seen with each individual antibody. Moreover, with the exception of one patient, mean plasma half-life of the MAb did not change significantly, suggesting that overall clearance mechanisms were not saturated by the consecutive doses of monoclonal antibody or significantly altered by the presence of HAMA.

UR - http://www.scopus.com/inward/record.url?scp=0024333403&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024333403&partnerID=8YFLogxK

M3 - Article

VL - 14

SP - 357

EP - 366

JO - Clinical Nuclear Medicine

JF - Clinical Nuclear Medicine

SN - 0363-9762

IS - 5

ER -